Scoreflex TRIO - Scoring PTCA Catheter
NCT05929313
Arterial Occlusive Diseases, Arteriosclerosis
Hangzhou, Zhejiang, China
View Trial DetailsNCT Number: NCT06678490
To collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the drug eluting Support C PTCA balloon catheter when used according to the Instructions for Use. Data will be collected in order to assess the long term safety and performance of the Support C Drug Coated Balloon (DCB) in routine clinical practice.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Krajska nemocnice Liberec, Liberec, Czechia
This multicenter, prospective registry population consists of consecutive patients with coronary heart disease who undergo percutaneous coronary intervention (PCI) and are intended to be or treated by the Support C Drug Coated Balloon (DCB) according to the Instructions for Use as part of routine clinical care. Approximately 278 patients from 8-12 centers in Europe will be entered into the registry. Patients in the registry are followed for three years. The registry is considered finished when all patients have completed the 36-month follow-up.
A follow-up is scheduled at the following timepoints: immediately post-procedure, 30 days, 6 months, 12 months, 24 months, 36 months. Follow-up is obtained by telephone contact with the patient or at a planned hospital visit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Note:
Exclusion criteria
Time frame: 12 months post procedure
Adjudicated, device-oriented, Target Lesion Failure (TLF) where TLF is defined as a composite of cardiac death (CD), non-fatal myocardial infarction (MI) not clearly attributable to a non-target vessel (TV-MI), or clinically driven target lesion revascularization (cd-TLR) (by PCI or coronary artery bypass grafting).
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 24 months, and 36 months
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 12 months, 24 months, and 36 months
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 12 months, 24 months, and 36 months
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 12 months, 24 months, and 36 months
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 12 months, 24 months, and 36 months
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 12 months, 24 months, and 36 months
Time frame: through hospital discharge (expected to be within 24 hours), 30 days, 6 months, 12 months, 24 months, and 36 months
Time frame: Index Procedure
Successful reaching of the target lesion, successful inflation and deflation of the balloon catheter, and a final residual stenosis after DCB treatment of ≤30% by visual assessment in the presence of grade 3 TIMI (Thrombolysis in Myocardial Infarction) flow, by visual estimation.
Time frame: Index Procedure
Procedure success: Successful balloon delivery, deployment and retrieval and no peri-procedural death, TV-MI or TVR.
OrbusNeich
Industry
PMCF Registry Study Paclitaxel-eluting Balloon Catheter Support C
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929313
Arterial Occlusive Diseases, Arteriosclerosis
Hangzhou, Zhejiang, China
View Trial DetailsNCT00000541
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00000555
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00000549
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details